Eli Lilly did not notify Roszdravnadzor of the termination of drug supplies to Russia
[ad_1]
Roszdravnadzor did not receive a notification from the American pharmaceutical company Eli Lilly about the termination of the supply of medicines to Russia. About it “Interfax” reported in the department.
“Roszdravnadzor received no letters from this company about stopping the supply of medicines,” the press service of Roszdravnadzor reported.
Today, March 28, it was reported that Eli Lilly became the second American pharmaceutical manufacturer after Bristol-Myers Squibb to finally leave Russia. The company may transfer its business in the country to Swiss Swixx Biopharma.
Eli Lilly supplies to Russia, including Humalog insulin, Trulicity, an antidiabetic drug, and Zenlistik, Cyramza, Alimta, and Gemzar cancer drugs. According to IQVIA, in 2022 Eli Lilly’s share in the Russian market was 0.52%, or RUB 11.6 billion.
As part of government procurement, Eli Lilly supplies Lisipro insulin. Some types of insulin from Eli Lilly can be replaced by Russian analogues, Nikolai Bespalov, RNC Pharma Development Director, said. However, he did not rule out the risk of temporary supply disruptions in the process of business transfer.
Read more in the publication “Kommersant” “Eli Lilly is barely visible”.
[ad_2]
Source link
